<DOC>
	<DOCNO>NCT00215722</DOCNO>
	<brief_summary>The first phase II trial cetuximab FOLFOX , 1st line therapy MCRC , present ASCO 2004 , show 81 % response rate , unexpected toxicity combination . This study aim establish efficacy safety combination cetuximab/XELOX first line therapy patient MCRC .</brief_summary>
	<brief_title>XELOX Plus Cetuximab First-Line Therapy Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>The phase II trial XELOX , demonstrate highly effective first-line treatment metastatic colorectal cancer , response rate similar regimen oxaliplatin infusional 5-FU/LV ( FOLFOX ) , convenient likely preferred patient health care provider . Cetuximab significant anti-cancer activity set chemo-resistant disease suggest much great degree benefit may ensue use early stage disease course . The first phase II trial cetuximab FOLFOX , 1st line therapy MCRC , present ASCO 2004 , show 81 % response rate , unexpected toxicity combination . This study aim establish efficacy safety combination cetuximab/XELOX first line therapy patient MCRC .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Signed write informed consent , prior studyspecific procedure Male female &gt; = 18 year age Histologically confirm adenocarcinoma colon rectum metastatic disease eligible surgery curative intent â€“ case unique metastatic lesion confirm biopsy ECOG performance status &lt; 1 study entry Immunohistochemical evidence EGFR expression tumour tissue Presence least one unidimensional measurable lesion diameter &gt; 20mm conventional CT scan MRI , 10mm spiral CT scan , accord RECIST criterion ( Index lesion ( ) must lie within irradiated area ) Have receive Chemotherapy regimen metastatic disease Life expectancy &gt; 3 month Neutrophils &gt; = 1.5 x 109/L , platelet count &gt; = 100 x 109/L , haemoglobin &gt; = 9 g/dL . Bilirubin level either normal 1.5 x ULN ASAT ALAT &lt; = 2.5 x ULN ( &lt; = 5 x ULN case liver metastasis ) Alkaline phosphatase &lt; = 2.5 x ULN &lt; = 5 x ULN case liver metastasis &lt; = 10 x ULN case bone metastases Serum creatinine &lt; = 1.5 x ULN CrCl &gt; 50 ml/min ( Cockroft Gault formula ) Negative Pregnancy test within one week treatment start , applicable Previous chemotherapy metastatic CRC adjuvant therapy oxaliplatin irinotecan . Adjuvant neoadjuvant therapy 5 FU derivative allow chemotherapy treatment free interval &gt; 6 month patient progress treatment Surgery ( exclude diagnostic biopsy ) irradiation within 4 week prior study entry Prior radiotherapy permit administered target lesion select study Concurrent chronic systemic immune therapy , chemotherapy , hormone therapy indicate study protocol Any investigational agent ( ) within 4 week prior entry Previous exposure EGFRpathway target therapy History evidence upon physical examination CNS disease ( e.g . primary brain tumour , seizure control standard therapy , brain metastasis history stroke ) Clinically relevant coronary artery disease history myocardial infarction within last 12 month Serious uncontrolled intercurrent infection , serious uncontrolled concomitant disease Acute subacute intestinal occlusion history inflammatory bowel disease Preexisting neuropathy &gt; grade 1 Known grade 3 4 allergic reaction component treatment . Any concurrent malignancy nonmelanoma skin cancer , carcinoma situ cervix . ( Patients previous malignancy without evidence disease &gt; = 5 year allow enter trial ) Known drug abuse/ alcohol abuse Legal incapacity limit legal capacity Medical psychological condition opinion investigator would permit patient complete study sign meaningful inform consent Pregnant lactate woman Sexually active male female ( childbearing potential ) unwilling practice contraception study Lack physical integrity upper gastrointestinal tract malabsorption syndrome Known dihydropyrimidine dehydrogenase deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>